Nick Webb's Avatar

Nick Webb

@profnickwebb.bsky.social

Paediatric nephrologist VP Medical Affairs / Clinical Development at Sobi Basel ๐Ÿ‡จ๐Ÿ‡ญ Anti-complement therapy for rare kidney disease ๐Ÿƒ and โ›ท๏ธand COYS

460 Followers  |  769 Following  |  2 Posts  |  Joined: 11.11.2024  |  1.8772

Latest posts by profnickwebb.bsky.social on Bluesky

๐Ÿ“ฃExcited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at โฒ๏ธ15:00 at the Square #nephrology #kidneydisease

06.06.2025 13:04 โ€” ๐Ÿ‘ 3    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

We are excited to be at #ERA25 in sunny Vienna๐Ÿ”…. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology

04.06.2025 12:34 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

๐Ÿ“ฃ Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on ๐Ÿ—“๏ธ June 6, ๐Ÿ•™ 10:00-11:00 (CEST) in Hall B

04.06.2025 15:31 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.

โฌ‡๏ธ Download the visual abstract: www.theisn.org/wp-co...

๐Ÿ“ฝ๏ธ Watch the industry webinar: academy.theisn.org/p...

Supported by @travererare.bsky.social

04.04.2025 12:00 โ€” ๐Ÿ‘ 6    ๐Ÿ” 4    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth

16.02.2025 10:51 โ€” ๐Ÿ‘ 18    ๐Ÿ” 3    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0

Sparsentan for FSGS isnโ€™t dead yetโ€ฆ ir.travere.com/news-release...

12.02.2025 13:13 โ€” ๐Ÿ‘ 3    ๐Ÿ” 4    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image Post image Post image Post image

Join the @theisn.org ! ๐ŸŒ
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky

07.02.2025 10:54 โ€” ๐Ÿ‘ 16    ๐Ÿ” 7    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
FDA greenlights first clinical trials for genetically modified pig kidney transplants in humans Two companies have received FDA approval to conduct clinical trials transplanting genetically modified pig kidneys into patients with kidney failure

Omg omg omg

www.kidneyfund.org/article/fda-...

07.02.2025 13:14 โ€” ๐Ÿ‘ 92    ๐Ÿ” 18    ๐Ÿ’ฌ 5    ๐Ÿ“Œ 1
Annual Data Report | USRDS Unites States Renal Data System Annual Data Report

The 2024 USRDS report is out (a few weeks ago actually)

usrds-adr.niddk.nih.gov/2024

Itโ€™s a treasure trove of data for nephrology nerds, aka all of #NephSky

So, short ๐Ÿงถ on ESRD incidence/prevalence

17.11.2024 01:37 โ€” ๐Ÿ‘ 74    ๐Ÿ” 20    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 1

Fascinating - didnโ€™t learn this at medical school!

16.11.2024 21:51 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

This is so very helpful - thanks for putting it all together

16.11.2024 20:01 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Sobi and Apellisโ€™ pegcetacoplan shows promise in phase 3 rare kidney disease study - PMLiVE There are currently no treatments that target the underlying cause of C3G or IC-MPGN

The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth

14.08.2024 15:37 โ€” ๐Ÿ‘ 9    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

๐Ÿซ˜๐ŸงฌComplement testing in patients with C3 Glomerulopathy

doi.org/10.1093/ndt/...

@ndt journal

14.11.2024 10:25 โ€” ๐Ÿ‘ 15    ๐Ÿ” 5    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0

@profnickwebb is following 20 prominent accounts